Reply to the letter to the editor 'ESMO-MCBS v1.1: statistical and patient relevant shortcomings' by Emprechtinger et al

Affiliations

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: MCBS@esmo.org.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
³ Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
⁴ ESMO Head Office, European Society for Medical Oncology, Lugano, Switzerland.
⁵ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁶ Department of Statistics, Athens University of Economics and Business, Athens.
⁷ Frontier Science Foundation-Hellas, Athens, Greece.
⁸ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁹ Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
¹⁰ Division of Oncology, Medical University Vienna, Vienna, Austria.
¹¹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Free article

Comment

N I Cherny et al. Ann Oncol. 2018.

Free article

. 2018 May 1;29(5):1335-1338.

doi: 10.1093/annonc/mdy108.

¹ Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: MCBS@esmo.org.
² Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
³ Jules Bordet Institute, Université Libre de Bruxelles, Brussels, Belgium.
⁴ ESMO Head Office, European Society for Medical Oncology, Lugano, Switzerland.
⁵ Methodology Direction, EORTC Headquarters, Brussels, Belgium.
⁶ Department of Statistics, Athens University of Economics and Business, Athens.
⁷ Frontier Science Foundation-Hellas, Athens, Greece.
⁸ Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
⁹ Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
¹⁰ Division of Oncology, Medical University Vienna, Vienna, Austria.
¹¹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

No abstract available

Comment on

ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310. Ann Oncol. 2017. PMID: 28945867
Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules.
Dafni U, Karlis D, Pedeli X, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski CC, Piccart MJ, de Vries EGE, Latino NJ, Douillard JY, Cherny NI. Dafni U, et al. ESMO Open. 2017 Oct 9;2(4):e000216. doi: 10.1136/esmoopen-2017-000216. eCollection 2017. ESMO Open. 2017. PMID: 29067214 Free PMC article.
ESMO-MCBS v1.1: statistical and patient-relevant shortcomings.
Emprechtinger R, Grössmann N, Wild C. Emprechtinger R, et al. Ann Oncol. 2018 Apr 1;29(4):1070-1071. doi: 10.1093/annonc/mdy026. Ann Oncol. 2018. PMID: 29360917 No abstract available.